<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151813</url>
  </required_header>
  <id_info>
    <org_study_id>811289</org_study_id>
    <secondary_id>K01DA025073</secondary_id>
    <nct_id>NCT01151813</nct_id>
  </id_info>
  <brief_title>Human Behavioral Pharmacology Laboratory (HBPL) Study of Varenicline's Impact on Cocaine and Alcohol Craving</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II within-subjects double-blind placebo-controlled human laboratory study.&#xD;
      The purpose of the study is to determine the efficacy of varenicline (Chantix) for reducing&#xD;
      cue-induced cocaine and alcohol craving.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale Alcohol Craving</measure>
    <time_frame>average value over one week</time_frame>
    <description>Visual Analog Scale specific to alcohol craving. The VAS has a 100 mm line anchored by 0 and 100. Participants mark the line to indicate how strong their craving is for alcohol. 0 indicates no craving 100 indicates strongest possible craving.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale Cocaine Craving</measure>
    <time_frame>average value over one week</time_frame>
    <description>Visual Analog Scale specific to cocaine craving. The VAS has a 100 mm line anchored by 0 and 100. Participants mark the line to indicate how strong their craving is for cocaine. 0 indicated no craving, 100 represents the worst craving imaginable. The subject draws a hatch mark line along the line closer to where there current craving is rated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale Alcohol Craving 2</measure>
    <time_frame>average over one week</time_frame>
    <description>Visual Analog Scale specific to alcohol craving. The VAS has a 100 mm line anchored by 0 and 100. Participants mark the line to indicate how strong their craving is for alcohol. 0 indicated no craving, 100 represents the worst craving imaginable. The subject draws a hatch mark line along the line closer to where there current craving is rated. Closer to the 0 means less craving, closer to the 100 means more craving</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale Cocaine Craving 2</measure>
    <time_frame>average over one week</time_frame>
    <description>Visual Analog Scale specific to cocaine craving. The VAS has a 100 mm line anchored by 0 and 100. Participants mark the line to indicate how strong their craving is for cocaine. 0 indicated no craving, 100 represents the worst craving imaginable. The subject draws a hatch mark line along the line closer to where there current craving is rated. Closer to the 0 means less craving, closer to the 100 means more craving</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Varenicline, oral administration for 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, oral administration for 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Varenicline, oral target dose of 1.0 mg BID, one week titration.</description>
    <arm_group_label>Varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is male or female and is between 21 and 65 years of age.&#xD;
&#xD;
          2. The subject has used cocaine, alcohol, or cocaine and alcohol at least once per month&#xD;
             for at least the past year, and has used cocaine, alcohol, or cocaine and alcohol&#xD;
             within the past 30 days.&#xD;
&#xD;
          3. Live within a commutable distance of the Treatment Research Center (TRC) at the&#xD;
             Penn/VA Center for Studies of Addiction, University of Pennsylvania. We define this to&#xD;
             be a distance within the service area of Septa, within an hour drive, or a distance&#xD;
             that both the patient and Principal Investigator (PI) find acceptable.&#xD;
&#xD;
          4. Understands and signs the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Meets DSM-IV criteria for current dependence on any substance other than nicotine,&#xD;
             cocaine, alcohol or marijuana.&#xD;
&#xD;
          2. Subjects who are currently taking anti-depressant medications (e.g., SSRIs such as&#xD;
             citalopram)&#xD;
&#xD;
          3. Patients who are diagnosed during screening with clinical depression using the HAM-D&#xD;
             rating scale and present with a score &gt;10.&#xD;
&#xD;
          4. Subjects who are diagnosed with anxiety as diagnosed using the HAM-A anxiety scale&#xD;
             with a score &gt;17&#xD;
&#xD;
          5. Subjects who meet current- or lifetime DSM-IV criteria for a psychotic disorder (e.g.,&#xD;
             schizophrenia)&#xD;
&#xD;
          6. Requires treatment with any psychotropic medication (e.g., antidepressant,&#xD;
             antipsychotic, benzodiazepine, or mood stabilizing medication).&#xD;
&#xD;
          7. Subjects who test positive on the urine drug screen for any illicit drugs other than&#xD;
             cocaine and marijuana during screening will be allowed a single retest. Those&#xD;
             individuals who test positive for amphetamine during screening, given that they&#xD;
             provide a copy of a prescription, will only be included if they can safely discontinue&#xD;
             amphetamine use for the duration of the study. Subjects will need to provide a urine&#xD;
             free of all illicit drugs other than cocaine and marijuana at study onset to be&#xD;
             randomized. Subjects who test positive for any drugs other than marijuana prior to a&#xD;
             study session will be allowed a single retest and a chance to reschedule their&#xD;
             session. If the subject tests positive for any drug other than marijuana at the&#xD;
             retest, their participation in the study will be terminated.&#xD;
&#xD;
          8. Use of any investigational medication within the past 30 days.&#xD;
&#xD;
          9. Concomitant use of any one of the following drugs or classes of drugs:&#xD;
&#xD;
             Anti-depressant drugs such as citalopram, fluoxetine; antipsychotic drugs such as&#xD;
             haloperidol; benzodiazepines or other anxiolytic medications; Antihypertensive drugs&#xD;
             such as Reserpine, Verapamil; Blood thinners Medications used to treat respiratory&#xD;
             diseases such as theophylline; Trimethoprim; Cimetidine; Antiepileptic drugs (AEDs)&#xD;
             such as phenytoin or valproic acid.&#xD;
&#xD;
         10. Patients with a known hypersensitivity to varenicline.&#xD;
&#xD;
         11. Patients with severe unstable or serious medical illness such as a seizure disorder,&#xD;
             unstable cerebrovascular disease, bronchospastic disease, hyperthyroidism, or diabetes&#xD;
             mellitus.&#xD;
&#xD;
         12. Patients with known AIDS or other serious illnesses that may require hospitalization&#xD;
             during the study.&#xD;
&#xD;
         13. Female subjects who are pregnant, plan to become pregnant, are currently lactating, or&#xD;
             are of child-bearing potential and are not using acceptable methods of birth control;&#xD;
             acceptable methods of birth control would include:&#xD;
&#xD;
               1. Barrier method (diaphragm or condom)&#xD;
&#xD;
               2. Intrauterine progesterone contraceptive system&#xD;
&#xD;
               3. Levonorgesterel implant&#xD;
&#xD;
               4. Medroxyprogesterone acetate contraceptive injection, or&#xD;
&#xD;
               5. Oral contraceptives.&#xD;
&#xD;
         14. Patients with impaired renal function, as indicated by corrected creatinine clearance&#xD;
             below 60 ml/min as determined by the modified Cockcroft equation (CDC, 1986).&#xD;
&#xD;
         15. An unacceptable liver panel (liver function tests; LFTs) that may be indicative of&#xD;
             hepatic dysfunction.&#xD;
&#xD;
         16. Clinical laboratory tests (e.g., CBC, blood chemistries, urinalysis) outside normal&#xD;
             limits, as determined by PI.&#xD;
&#xD;
         17. History of significant heart disease or dysfunction (e.g., an arrhythmia which&#xD;
             required medication, Wolff Parkinson -White Syndrome, angina pectoris, documented&#xD;
             history of myocardial infarction, heart failure).&#xD;
&#xD;
         18. Electrocardiography (EKG) indicative of 1st degree heart block, sinus tachycardia,&#xD;
             left-axis deviation, non-specific ST or T-wave changes.&#xD;
&#xD;
         19. History of chest pain associated with cocaine use that prompted a visit to a&#xD;
             physician.&#xD;
&#xD;
         20. Any medical or psychological condition that could jeopardize the subject's safe&#xD;
             participation in the trial as determined by the PI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pennsylvania, Treatment Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 25, 2010</study_first_submitted>
  <study_first_submitted_qc>June 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <results_first_submitted>October 25, 2016</results_first_submitted>
  <results_first_submitted_qc>August 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2020</results_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Varenicline First, Then Placebo</title>
          <description>Varenicline, oral target dose of 1.0 mg BID, one week titration; followed by placebo, matched for one week.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Varenicline</title>
          <description>Placebo for one week, followed by Varenicline, oral target dose of 1.0 mg BID, one week titration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Within-subjects Design</title>
          <description>Varenicline, oral target dose of 1.0 mg BID, one week titration; placebo, matched for one week. Double-blind counterbalanced order</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Scale Alcohol Craving</title>
        <description>Visual Analog Scale specific to alcohol craving. The VAS has a 100 mm line anchored by 0 and 100. Participants mark the line to indicate how strong their craving is for alcohol. 0 indicates no craving 100 indicates strongest possible craving.</description>
        <time_frame>average value over one week</time_frame>
        <population>Comparing alcohol craving during Varenicline treatment in participants initially treated with Varenicline (Group 1) to those initially treated with Placebo (Group 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline First, Then Placebo</title>
            <description>Varenicline, oral target dose of 1.0 mg BID, one week titration; followed by placebo, matched for one week.</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then Varenicline</title>
            <description>Placebo for one week; followed by Varenicline, oral target dose of 1.0 mg BID, one week titration.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale Alcohol Craving</title>
          <description>Visual Analog Scale specific to alcohol craving. The VAS has a 100 mm line anchored by 0 and 100. Participants mark the line to indicate how strong their craving is for alcohol. 0 indicates no craving 100 indicates strongest possible craving.</description>
          <population>Comparing alcohol craving during Varenicline treatment in participants initially treated with Varenicline (Group 1) to those initially treated with Placebo (Group 2).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="35" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>.02</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Scale Cocaine Craving</title>
        <description>Visual Analog Scale specific to cocaine craving. The VAS has a 100 mm line anchored by 0 and 100. Participants mark the line to indicate how strong their craving is for cocaine. 0 indicated no craving, 100 represents the worst craving imaginable. The subject draws a hatch mark line along the line closer to where there current craving is rated.</description>
        <time_frame>average value over one week</time_frame>
        <population>Comparing cocaine craving during Varenicline treatment in participants initially treated with Varenicline (Group 1) to those initially treated with Placebo (Group 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline First, Then Placebo</title>
            <description>Varenicline, oral target dose of 1.0 mg BID, one week titration; placebo, matched for one week.</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then Varenicline</title>
            <description>Placebo for one week; followed by Varenicline, oral target dose of 1.0 mg BID, one week titration.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale Cocaine Craving</title>
          <description>Visual Analog Scale specific to cocaine craving. The VAS has a 100 mm line anchored by 0 and 100. Participants mark the line to indicate how strong their craving is for cocaine. 0 indicated no craving, 100 represents the worst craving imaginable. The subject draws a hatch mark line along the line closer to where there current craving is rated.</description>
          <population>Comparing cocaine craving during Varenicline treatment in participants initially treated with Varenicline (Group 1) to those initially treated with Placebo (Group 2).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="65" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Scale Alcohol Craving 2</title>
        <description>Visual Analog Scale specific to alcohol craving. The VAS has a 100 mm line anchored by 0 and 100. Participants mark the line to indicate how strong their craving is for alcohol. 0 indicated no craving, 100 represents the worst craving imaginable. The subject draws a hatch mark line along the line closer to where there current craving is rated. Closer to the 0 means less craving, closer to the 100 means more craving</description>
        <time_frame>average over one week</time_frame>
        <population>Comparing alcohol craving during Placebo treatment in participants initially treated with Varenicline (Group 1) to those initially treated with Placebo (Group 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline First, Then Placebo</title>
            <description>Varenicline, oral target dose of 1.0 mg BID, one week titration; followed by placebo, matched for one week.</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then Varenicline</title>
            <description>Placebo for one week; followed by Varenicline, oral target dose of 1.0 mg BID, one week titration.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale Alcohol Craving 2</title>
          <description>Visual Analog Scale specific to alcohol craving. The VAS has a 100 mm line anchored by 0 and 100. Participants mark the line to indicate how strong their craving is for alcohol. 0 indicated no craving, 100 represents the worst craving imaginable. The subject draws a hatch mark line along the line closer to where there current craving is rated. Closer to the 0 means less craving, closer to the 100 means more craving</description>
          <population>Comparing alcohol craving during Placebo treatment in participants initially treated with Varenicline (Group 1) to those initially treated with Placebo (Group 2).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="55" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Scale Cocaine Craving 2</title>
        <description>Visual Analog Scale specific to cocaine craving. The VAS has a 100 mm line anchored by 0 and 100. Participants mark the line to indicate how strong their craving is for cocaine. 0 indicated no craving, 100 represents the worst craving imaginable. The subject draws a hatch mark line along the line closer to where there current craving is rated. Closer to the 0 means less craving, closer to the 100 means more craving</description>
        <time_frame>average over one week</time_frame>
        <population>Comparing cocaine craving during Placebo treatment in participants initially treated with Varenicline (Group 1) to those initially treated with Placebo (Group 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline First, Then Placebo</title>
            <description>Varenicline, oral target dose of 1.0 mg BID, one week titration; placebo, matched for one week.</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then Varenicline</title>
            <description>Placebo for one week; followed by Varenicline, oral target dose of 1.0 mg BID, one week titration.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale Cocaine Craving 2</title>
          <description>Visual Analog Scale specific to cocaine craving. The VAS has a 100 mm line anchored by 0 and 100. Participants mark the line to indicate how strong their craving is for cocaine. 0 indicated no craving, 100 represents the worst craving imaginable. The subject draws a hatch mark line along the line closer to where there current craving is rated. Closer to the 0 means less craving, closer to the 100 means more craving</description>
          <population>Comparing cocaine craving during Placebo treatment in participants initially treated with Varenicline (Group 1) to those initially treated with Placebo (Group 2).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="80" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>through study completion, two weeks</time_frame>
      <desc>Participants were asked to report adverse events at each study visit by nurses using a checklist of known (previously reported) adverse events, as well as novel adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Varenicline</title>
          <description>While receiving Varenicline, oral target dose of 1.0 mg BID, one week titration</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>While receiving Placebo, one week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jennifer Plebani</name_or_title>
      <organization>UPenn</organization>
      <phone>215-222-3200 ext 152</phone>
      <email>jplebani@upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

